国家储备流感A(H5N1)疫苗储存12年后的安全性与免疫原性
美国BARDA开展随机双盲2期临床研究,评估NPIVS中储存10-12年的A(H5N1)抗原(联合或不用储存2-7年的MF59佐剂)在健康成人中的安全性和免疫原性。结果显示疫苗耐受良好,不良事件多为轻度,最久储存抗原的免疫原性未下降;MF59佐剂组抗体峰值反应更高,且疫苗诱导对当代A(H5)毒株的交叉反应抗体。
要点
- 储存10-12年的A(H5N1)抗原免疫原性未下降,安全性与历史数据相似。
- MF59佐剂疫苗抗体峰值反应高于无佐剂疫苗,与抗原剂量无关。
- 疫苗可诱导对当代A(H5)流感病毒的交叉反应抗体。
核心结论
- 储存于NPIVS的A(H5N1)疫苗在健康成人中按两剂方案接种仍安全、耐受且具有免疫原性,尽管抗原或MF59佐剂储存时间较长。
研究设计与样本
- BARDA开展的随机双盲2期临床研究,使用储存10-12年的最久A(H5N1)抗原,联合或不联合储存2-7年的MF59佐剂。
主要发现
- 储备疫苗耐受良好,不良事件一般为轻度,最久储存A(H5N1)疫苗的免疫原性未下降。
- 与无佐剂疫苗相比,MF59佐剂疫苗的抗体峰值反应更高,与抗原剂量无关。
- 接种A(H5N1)疫苗抗原可诱导对当代流行A(H5)流感病毒的交叉反应抗体。
关键数值与推荐
- 不良事件的频率、类型和严重程度与A(H5N1)疫苗及MF59佐剂的历史临床研究数据相似。
- 健康成人按两剂疫苗方案接种时具有免疫原性。
临床怎么用
- 支持在流感大流行时使用长期储备的A(H5N1)疫苗和MF59佐剂,维持应急准备能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As part of the U.S. Department of Health and Human Services (HHS) Pandemic Influenza Plan preparedness and response strategy, the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program was established by the Biomedical Advanced Research and Development Authority (BARDA) in 2005 with the goal of building and maintaining a stockpile of vaccines for influenza viruses with pandemic potential to vaccinate 20 million people in the critical workforce in the event of a pandemic. The NPIVS program continuously monitors the integrity of influenza vaccine antigens and adjuvants stored within the stockpile. In addition to monitoring physical and chemical properties in stability studies, it is important to regularly assess the safety and immunogenicity of stockpiled vaccines and adjuvants to maintain preparedness for use in the event of an influenza pandemic. METHODS: BARDA conducted a randomized, double-blinded Phase 2 clinical study with the oldest stockpiled influenza A(H5N1) antigen, stored over the previous 10-12 years administered with or without MF59® adjuvant, stored over the previous 2-7 years at the time of vaccination. RESULTS: Stockpiled vaccines were well-tolerated, adverse events were generally mild, and there was no drop in immunogenicity to the oldest stockpiled A(H5N1) vaccine. Compared to unadjuvanted vaccine, greater peak antibody responses were observed in subjects who were vaccinated with MF59-adjuvanted vaccines, regardless of antigen dose. Vaccination with the A(H5N1) vaccine antigen also results in cross-reactive antibody responses to contemporary circulating strains of A(H5) influenza viruses. CONCLUSIONS: The frequency, type, and severity of AEs observed during this study are similar to historical clinical study data with A(H5N1) vaccines and MF59 adjuvant indicating that a stockpiled A(H5N1) vaccine appears to remain safe and tolerable. The vaccines were immunogenic when administered as a two-dose vaccine regimen in healthy adults, despite extended storage of HA antigen or MF59 adjuvant within the NPIVS. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02680002.
引用
- Oshansky CM, Zhou J, Gao Y, et al. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS). Vaccine. 2018. PMID: 30553570. doi:10.1016/j.vaccine.2018.11.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。